Reporting owner · CIK 0001106578

Rothblatt Martine A

Visual SEC Form 4 history across 2 companies, 373 transactions and 28 filings.

CHAIR, CEOChairperson & CEOUNITED THERAPEUTICS Corp
Open-market mix
Latest filingSep 02, 2026, 08:34 PM
Filings28Form 4 records
Buying$863.9K1 purchases
Selling$129.3M313 sales
Net value−$128.5MBuys minus sells
Companies25 securities
Most recentSep 01, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
180900-90-180Jan 26179Mar 26125May 26102Aug 267Sep 26

Net value flow

Buys minus sells

Jan 26
$0
Mar 26
−$65.4M
May 26
−$9.1M
Aug 26
−$49M
Sep 26
−$4.9M

Transaction texture

Ownership and ticket size

Average P/S size$414.6K
Median P/S size$306.6K
Direct242
Indirect131
Sep 01, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern256Derivative Transactionfiling-context27Director Buyrole1Direct Ownershipfiling-context242Large Holdings Increaseholdings10Large Holdings Reductionholdings39Large Salesize81Repeat Sellerpattern30110b5-1 Detectedfiling-context357

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at UNITED THERAPEUTICS Corp on Sep 01, 2026 valued at $41,330.

Review SEC filing
Latest buy

buy at UNITED THERAPEUTICS Corp on May 26, 2026 valued at $863,947.

Review SEC filing
Latest sale

sale at UNITED THERAPEUTICS Corp on Sep 01, 2026 valued at $41,330.

Review SEC filing

Associated companies

Visual map of known reporting history

UTHRUNITED THERAPEUTICS Corp372 transactions · latest Sep 02, 2026, 08:34 PMBETABETA Technologies, Inc.1 transactions · latest Feb 04, 2026, 01:45 AM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-1200-$10.4MS
Cluster Selling Repeat Seller 10b5-1 Detected
0.0%08/3108/28
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-16-$314kS
Cluster Selling Repeat Seller 10b5-1 Detected
0.0%08/3108/28
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-1517-$27.0MS
Cluster Selling Repeat Seller 10b5-1 Detected
0.0%08/3108/28
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-1286-$14.9MS
Cluster Selling Repeat Seller 10b5-1 Detected
0.0%08/3108/28
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-1751-$39.0MS
Cluster Selling Repeat Seller 10b5-1 Detected
0.0%08/3108/28
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-1412-$21.3MS
Cluster Selling Repeat Seller 10b5-1 Detected
0.0%08/3108/28
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-11.34k-$69.7MS
Cluster Selling Large Sale Repeat Seller+1
0.0%08/3108/28
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-11.48k-$76.8MS
Cluster Selling Large Sale Repeat Seller+1
0.0%08/3108/28
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-12.38k-$123MS
Cluster Selling Large Sale Repeat Seller+1
0.0%08/3108/28
UTHRROTHBLATT MARTINE A
CHAIRCEO
sale10b5-11.63k-$84.0MS
Cluster Selling Large Sale Repeat Seller+1
0.0%08/3108/28

Rothblatt Martine A Insider Activity FAQ

SEC Form 4 context

Who is Rothblatt Martine A?

Rothblatt Martine A is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001106578.

Which companies has Rothblatt Martine A reported transactions for?

UNITED THERAPEUTICS Corp, BETA Technologies, Inc.

When was Rothblatt Martine A's latest insider buy?

buy at UNITED THERAPEUTICS Corp on May 26, 2026 valued at $863,947.

When was Rothblatt Martine A's latest insider sale?

sale at UNITED THERAPEUTICS Corp on Sep 01, 2026 valued at $41,330.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.